CJC-1295 vs Tesamorelin
The distinction that mattersTesamorelin is a different GRF(1-29) analogue that completed phase 3 and is FDA-approved for HIV-associated lipodystrophy — the same indication in which CJC-1295's own phase 2 was terminated and never reported. Calling CJC-1295 a "tesamorelin cousin" borrows an approval and an efficacy dataset belonging to another molecule while leaving behind the label that comes with them, which requires IGF-1 and glucose monitoring and forbids use in active malignancy.
These are not equivalent in evidence Tesamorelin is rated 5/5 and CJC-1295 is rated 2/5 — a gap of 3 levels on our scale. Similar marketing does not mean similar proof.
| CJC-1295 Research Use Only | Tesamorelin FDA Approved | |
|---|---|---|
| Evidence rating |
2/5 Limited
Evidence rating 2 out of 5: Limited
|
5/5 Very strong
Evidence rating 5 out of 5: Very strong
|
| Regulatory status | Investigational; clinical development discontinued. Not approved. Widely sold grey-market. | FDA-approved for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy |
| Category | Growth Hormone Axis | Growth Hormone Axis |
| Drug class | GHRH analog; the DAC version bears a maleimide linker that binds serum albumin | Stabilised growth hormone-releasing hormone (GHRH) analog |
| Route | Subcutaneous (research) | Subcutaneous, once daily |
| Half-life | CJC-1295 with DAC: 5.8–8.1 days in healthy adults, once bound to albumin. CJC-1295 without DAC (modified GRF(1-29)): minutes — no human half-life has ever been published for it, and the figure usually quoted is inferred from sermorelin and native GRF(1-29). | 8–11 minutes subcutaneously on the current FDA labels (EGRIFTA SV and WR); the discontinued 2010 formulation gave 26–38 minutes. |
| Sequence length | 30 residues | 44 residues |
| Molecular weight | 3,647.3 Da | 5,135.9 Da |
| Studied in | CJC-1295 with DAC: two randomised, double-blind, placebo-controlled ascending-dose trials in healthy adults running 28 and 49 days, measuring GH, IGF-1 and drug pharmacokinetics, plus one overnight GH-pulsatility study. One phase 2 efficacy trial — 12 weeks, multicentre, randomised, double-blind, placebo-controlled, in HIV-associated visceral adiposity — was terminated in July 2006 with no results posted or published, and it is the only CJC-1295 study ever entered on ClinicalTrials.gov. The peptide sold without DAC has no controlled human study at all. | Two phase 3 trials in HIV-associated lipodystrophy; investigator-led studies in NAFLD and in HIV-associated cognitive complaints. |
| Who should avoid it |
|
|
| Legal status | Not approved for human use in the US, EU or UK. Sale for human consumption is unlawful. | Prescription drug; on-label use is narrow. Compounded GHRH analogs sold for anti-aging are a different regulatory situation entirely. |
Benefits — CJC-1295
- Sustained GH and IGF-1 elevation
Phase 1 data showed multi-day increases in GH and IGF-1 after a single DAC dose — the pharmacology works as designed.
- Reduced injection frequency
The DAC version requires weekly rather than daily dosing.
- Synergy with ghrelin agonists
Combining a GHRH analog with a GHRP produces a larger GH pulse than either alone — well established in pituitary physiology.
- GH pulsatility survives continuous stimulation
Healthy young men sampled every 20 minutes across an overnight period, before and one week after a single injection of the DAC version, showed unchanged GH pulse frequency and amplitude while trough GH rose about seven-fold; mean GH rose 46% and IGF-1 45%. Unlike injected growth hormone, the rise stays pituitary-mediated rather than replacing pituitary output. One small single-dose study, one lab.
- The response appears to plateau rather than climb
In that same study the two doses compared produced no different GH or IGF-1 response, and the IGF-1 rise correlated with no measured parameter of GH secretion — consistent with a ceiling set by somatotroph capacity rather than by how much drug arrives. Never confirmed in a larger study.
Benefits — Tesamorelin
- Selective visceral fat reduction
Roughly 15–18% reduction in visceral adipose tissue by CT over 26 weeks, without equivalent loss of subcutaneous fat.
- Triglyceride improvement
Consistent reductions in triglycerides accompanied the visceral fat loss.
- Liver fat reduction
An NIH-supported randomized trial showed reduced hepatic fat and slowed fibrosis progression in people with HIV and NAFLD.
- Physiological GH pattern
Preserves pituitary feedback, so it does not suppress the axis the way exogenous GH does.
Risks & cons — CJC-1295
- Continuous GH exposure is non-physiological
Natural GH is pulsatile. Chronic flat elevation is the pattern seen in acromegaly, and its long-term consequences with this drug are untested.
- Development discontinued
The sponsor stopped work; no phase 2 or 3 efficacy or safety data exist.
- Insulin resistance and glucose elevation
Expected with sustained GH/IGF-1 elevation.
- Fluid retention, paraesthesia, carpal tunnel
GH-excess symptoms reported by users.
- Theoretical cancer promotion
IGF-1 is mitogenic; chronic elevation in people with occult neoplasia is a genuine unknown.
Risks & cons — Tesamorelin
- Glucose intolerance
GH is counter-regulatory to insulin; fasting glucose and HbA1c can rise, occasionally unmasking diabetes.
- Fluid retention, arthralgia, carpal tunnel
Classic GH-excess side effects, dose-related.
- Contraindicated in active malignancy
GH/IGF-1 elevation is avoided where a growth-sensitive tumour may be present.
- Benefit reverses on stopping
Visceral fat returns after discontinuation; it is chronic therapy.
- Injection-site reactions and hypersensitivity
Common; anaphylaxis has been reported rarely.
A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.